Literature DB >> 15067127

Illegitimate WNT signaling promotes proliferation of multiple myeloma cells.

Patrick W B Derksen1, Esther Tjin, Helen P Meijer, Melanie D Klok, Harold D MacGillavry, Marinus H J van Oers, Henk M Lokhorst, Andries C Bloem, Hans Clevers, Roel Nusse, Ronald van der Neut, Marcel Spaargaren, Steven T Pals.   

Abstract

The unrestrained growth of tumor cells is generally attributed to mutations in essential growth control genes, but tumor cells are also influenced by signals from the environment. In multiple myeloma (MM), the factors and signals coming from the bone marrow microenvironment are possibly even essential for the growth of the tumor cells. As targets for intervention, these signals may be equally important as mutated oncogenes. Given their oncogenic potential, WNT signals form a class of paracrine growth factors that could act to influence MM cell growth. In this paper, we report that MM cells have hallmarks of active WNT signaling, whereas the cells have not undergone detectable mutations in WNT signaling genes such as adenomatous polyposis coli and beta-catenin (CTNNB1). We show that the malignant MM plasma cells overexpress beta-catenin, including its N-terminally unphosphorylated form, suggesting active beta-catenin/T cell factor-mediated transcription. Further accumulation and nuclear localization of beta-catenin, and/or increased cell proliferation, was achieved by stimulation of WNT signaling with either Wnt3a, LiCl, or the constitutively active S33Y mutant of beta-catenin. In contrast, by blocking WNT signaling by dominant-negative T cell factor, we can interfere with the growth of MM cells. We therefore suggest that MM cells are dependent on an active WNT signal, which may have important implications for the management of this incurable form of cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15067127      PMCID: PMC395933          DOI: 10.1073/pnas.0305855101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

Review 1.  Linking colorectal cancer to Wnt signaling.

Authors:  M Bienz; H Clevers
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

Review 2.  Wnt signaling and cancer.

Authors:  P Polakis
Journal:  Genes Dev       Date:  2000-08-01       Impact factor: 11.361

3.  Somatic activation of beta-catenin bypasses pre-TCR signaling and TCR selection in thymocyte development.

Authors:  F Gounari; I Aifantis; K Khazaie; S Hoeflinger; N Harada; M M Taketo; H von Boehmer
Journal:  Nat Immunol       Date:  2001-09       Impact factor: 25.606

4.  Functional interaction of beta-catenin with the transcription factor LEF-1.

Authors:  J Behrens; J P von Kries; M Kühl; L Bruhn; D Wedlich; R Grosschedl; W Birchmeier
Journal:  Nature       Date:  1996-08-15       Impact factor: 49.962

5.  XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos.

Authors:  M Molenaar; M van de Wetering; M Oosterwegel; J Peterson-Maduro; S Godsave; V Korinek; J Roose; O Destrée; H Clevers
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

Review 6.  Lessons from hereditary colorectal cancer.

Authors:  K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

7.  The beta-catenin--TCF-1 pathway ensures CD4(+)CD8(+) thymocyte survival.

Authors:  V Ioannidis; F Beermann; H Clevers; W Held
Journal:  Nat Immunol       Date:  2001-08       Impact factor: 25.606

8.  Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma.

Authors:  V Korinek; N Barker; P J Morin; D van Wichen; R de Weger; K W Kinzler; B Vogelstein; H Clevers
Journal:  Science       Date:  1997-03-21       Impact factor: 47.728

9.  Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells.

Authors:  V Stambolic; L Ruel; J R Woodgett
Journal:  Curr Biol       Date:  1996-12-01       Impact factor: 10.834

10.  An HMG-box-containing T-cell factor required for thymocyte differentiation.

Authors:  S Verbeek; D Izon; F Hofhuis; E Robanus-Maandag; H te Riele; M van de Wetering; M Oosterwegel; A Wilson; H R MacDonald; H Clevers
Journal:  Nature       Date:  1995-03-02       Impact factor: 49.962

View more
  130 in total

1.  Tumourigenic characteristics of embryonal carcinoma cells as a model for studying tumour progression of human embryonic stem cells.

Authors:  S Yang; G Lin; L Deng; G-X Lu
Journal:  Cell Prolif       Date:  2012-08       Impact factor: 6.831

2.  Targeting bone as a therapy for myeloma.

Authors:  Ping Wu; Gareth J Morgan
Journal:  Cancer Microenviron       Date:  2011-08-11

3.  Differential inhibition of Wnt-3a by Sfrp-1, Sfrp-2, and Sfrp-3.

Authors:  Lisa M Galli; Tiffany Barnes; Tina Cheng; Lisa Acosta; Adolph Anglade; Karl Willert; Roel Nusse; Laura W Burrus
Journal:  Dev Dyn       Date:  2006-03       Impact factor: 3.780

Review 4.  Microarray-based understanding of normal and malignant plasma cells.

Authors:  John De Vos; Dirk Hose; Thierry Rème; Karin Tarte; Jérôme Moreaux; Karéne Mahtouk; Michel Jourdan; Hartmut Goldschmidt; Jean-François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Immunol Rev       Date:  2006-04       Impact factor: 12.988

5.  β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Authors:  Mona Anand; Raymond Lai; Pascal Gelebart
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

6.  Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.

Authors:  Michelle M McDonald; Michaela R Reagan; Scott E Youlten; Sindhu T Mohanty; Anja Seckinger; Rachael L Terry; Jessica A Pettitt; Marija K Simic; Tegan L Cheng; Alyson Morse; Lawrence M T Le; David Abi-Hanna; Ina Kramer; Carolyne Falank; Heather Fairfield; Irene M Ghobrial; Paul A Baldock; David G Little; Michaela Kneissel; Karin Vanderkerken; J H Duncan Bassett; Graham R Williams; Babatunde O Oyajobi; Dirk Hose; Tri G Phan; Peter I Croucher
Journal:  Blood       Date:  2017-05-17       Impact factor: 22.113

Review 7.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

8.  Anthelmintic pyrvinium pamoate blocks Wnt/β-catenin and induces apoptosis in multiple myeloma cells.

Authors:  Fang Xu; Yingjie Zhu; Yuhong Lu; Zhi Yu; Jun Zhong; Yangqiu Li; Jingxuan Pan
Journal:  Oncol Lett       Date:  2018-02-09       Impact factor: 2.967

Review 9.  Target identification and validation in systemic autoimmunity.

Authors:  Stanford L Peng
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 10.  WNT signalling pathways as therapeutic targets in cancer.

Authors:  Jamie N Anastas; Randall T Moon
Journal:  Nat Rev Cancer       Date:  2013-01       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.